Super Important Biotech and Drug Stock Events for November

BOSTON ( TheStreet) -- The November calendar of biotech and drug stock events.

Nov. 3

Earnings: Arena Pharmaceuticals (ARNA) , MannKind (MNKD) Neurocrine Biosciences (NBIX)

Nov. 4

Earnings: Ironwood Pharma (IRWD) , Jazz Pharma (JAZZ) , Halozyme Therapeutics (HALO) , Exelixis (EXEL) , Myriad Genetics (MYGN) , Pharmacylics (PCYC) , Regeneron Pharma (REGN)

FDA releases briefing documents for Oncologic Drug Advisory Committee meeting scheduled for Nov. 6: Rockwell Medical  (RMTI) (Triferic) and Novartis (NVS) (Faridak.)

Nov. 5

Earnings: Actavis (ACT) Regulus Therapeutics (RGLS) , Vivus (VVUS)  , Alnylam Pharma (ALNY)

FDA approval decision: Aeterna Zentaris (AEZS) Macrilen for growth hormone deficiency.

The Medicines Co. (MDCO) Investor/Analyst meeting.

Nov. 6

Earnings: Amarin (AMRN) , AstraZeneca (AZN) , Epizyme (EPZM) , Hyperion Therapeutics (HPTX)   Keryx Pharma (KERX) , Medivation (MDVN) , NewLink Genetics (NLNK) , Raptor Pharma (RPTP) , Tekmira Pharma (TKMR) , Spectrum Pharma (SPPI) , Sarepta Therapeutics (SRPT)

FDA Oncologic Drugs Advisory Committee: Rockwell Medical (Triferic) and Novaris (Faridak.)

Nov. 7

Earnings: Agios Pharma (AGIO) , Intercept Pharma (ICPT)

Nov. 10

Intercept Pharma Analyst/Investor Day.

Nov. 13

Earnings: Retrophin (RTRX)

Nov. 18

AstraZeneca Analyst/Investor Day

Ligand (LGND) Analyst/Investor Day

Nov. 19 

FDA approval decision: Genentech/Roche  (RHHBY) Avastin for recurrent, platinum-resistant ovarian cancer.

Nov. 26 

FDA approval decision: Avanir Pharma (AVNR)  AVP-825 for migraine.

November Medical Meetings:

Nov. 2-7: Obesity Week: Orexigen Therapeutics (OREX) , Arena Pharma ARNA

Nov. 7-11: American Association for the Study of Liver Disease (AASLD): Gilead Sciences (GILD) , Merck (MRK) , Bristol-Myers Squibb (BMY) , Abbvie ABBV, Enanta Pharma (ENTA) , Arrowhead Research (ARWR) , Conatus Pharma (CNAT) , Genfit ALGFT, Alnylam Pharma (ALNY)

Nov. 9: International Gynecologic Cancer Society: Oxigene (OXGN) fosbretabulin+Avastin phase II recurrent ovarian cancer.

Nov. 11-16: American Society of Nephrology: Acceleron Pharma (XLRN)

Nov. 13-16: Society of Neuro-Oncology annual meeting: Celldex Therapeutics (CLDX) , ImmunoCellular Therapeutics (IMUC)

Nov. 15-19: American Heart Association Scientific Sessions: Merck, NeoStem (NBS) , Regeneron Pharma  

Nov. 18-21: EORTC-NCI-AACR: Agios Pharma, Bind Therapeutics (BIND) , Clovis Oncology 

Clinical Data: 

XOMA (XOMA) Gevokizumab (Behcet's Syndrome), Achillion Pharma (ACHN) ACH-3422 (hepatitis C)

Source: BioMedTracker.com, company reports and TheStreet research.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

More from Stocks

What You Need to Know About Facebook and Europe's New Privacy Rules

What You Need to Know About Facebook and Europe's New Privacy Rules

8 Bold Moves General Motors Could Make to Rev Up Its Battered Stock Price

8 Bold Moves General Motors Could Make to Rev Up Its Battered Stock Price

Is Your Investment Portfolio Prepared for Trade Wars, Inflation and More Trump?

Is Your Investment Portfolio Prepared for Trade Wars, Inflation and More Trump?

GE Is Too Opaque, Too Diversified and Too Poorly Managed: Doug Kass Insider

GE Is Too Opaque, Too Diversified and Too Poorly Managed: Doug Kass Insider

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric